Indication-specific pricing for cancer drugs
JAMA
.
2014 Oct;312(16):1629-30.
doi: 10.1001/jama.2014.13235.
Author
Peter B Bach
1
Affiliation
1
Health Outcomes Research Group, Memorial Sloan-Kettering Cancer Center, New York, New York.
PMID:
25279433
DOI:
10.1001/jama.2014.13235
No abstract available
MeSH terms
Antineoplastic Agents / economics*
Cost Control
Drug Costs*
Europe
Health Policy
United States
Substances
Antineoplastic Agents